Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Onyx BiotecNSE:ONYX -2.63%13 PB Ratio is 1.21 as of Jul. 22, 2026, which is 18% below its 10-year median of 1.48. GuruFocus rates NSE:ONYX with a GF Score™ of 13/100. The stock has 6 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Onyx Biotec ranks better than 72.26% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-22), Onyx Biotec's share price is ₹37.00. Onyx Biotec's Book Value per Share for the quarter that ended in Mar. 2026 was ₹30.69. Hence, Onyx Biotec's PB Ratio of today is 1.21.
The historical rank and industry rank for Onyx Biotec's PB Ratio or its related term are showing as below:
NSE:ONYX'
s PB Ratio Range Over the Past 10 Years
Min: 0.96 Med: 1.48 Max: 6.46
Current: 1.21
During the past 5 years, Onyx Biotec's highest PB Ratio was 6.46. The lowest was 0.96. And the median was 1.48.
NSE:ONYX's PB Ratio is ranked better than 72.26% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs NSE:ONYX: 1.21
During the past 12 months, Onyx Biotec's average Book Value Per Share Growth Rate was 1.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 45.60% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Onyx Biotec was 50.30% per year. The lowest was 45.60% per year. And the median was 47.95% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Onyx Biotec PB Ratio Related Terms
Onyx Biotec PB Ratio Historical Data
* Premium members only.
The historical data trend for Onyx Biotec's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Onyx Biotec's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onyx Biotec PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Onyx Biotec's PB Ratio distribution charts can be found below:
* The bar in red indicates where Onyx Biotec's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Onyx Biotec's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Onyx Biotec (NSE:ONYX) has a PB Ratio of 1.21 as of Jul. 22, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Onyx Biotec and its competitors. This is 18% below median its historical median of 1.48. Over the past decade, Onyx Biotec's PB Ratio has ranged from 0.96 to 6.46. According to the industry distribution chart, Onyx Biotec ranks #218 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 27.7%.
Is Onyx Biotec's PB Ratio too high?
Onyx Biotec's current PB Ratio of 1.21 is 18% below median its 10-year median of 1.48. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 6.46. The Medical Devices & Instruments industry median PB Ratio is 2.05. Onyx Biotec's value of 1.21 is 41% below this industry median. Based on the distribution chart, Onyx Biotec ranks #218 out of 786 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Onyx Biotec has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Onyx Biotec's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Onyx Biotec ranks #218 out of 786 companies for PB Ratio. This puts Onyx Biotec in the upper half of its industry. The industry median PB Ratio is 2.05. Onyx Biotec's value of 1.21 is 41% below this benchmark. Historically, Onyx Biotec's own PB Ratio has ranged from 0.96 to 6.46 over the past decade. While the company's 10-year median is 1.48 vs. the industry median of 2.05, Onyx Biotec has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onyx Biotec's current PB Ratio of 1.21 is 41% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Onyx Biotec and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onyx Biotec's current PB Ratio is 1.21, which is 18% below median its own 10-year median of 1.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Biotec stock overvalued right now?
Onyx Biotec (NSE:ONYX) has a current PB Ratio of 1.21. The current PB Ratio is 1.21, which is 18% below median its 10-year median of 1.48 and 41% below the Medical Devices & Instruments industry median of 2.05. Onyx Biotec's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Onyx Biotec (NSE:ONYX), the current PB Ratio is 1.21 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Onyx Biotec Ltd is engaged in healthcare segment and offering Sterile Pharmaceutical products ,and acts as a pharmaceutical contract manufacturer. It offering products such as Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas. Key revenue is generated from Sterile Water for Injections .
13GF Score
Get the complete analysis for NSE:ONYX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONYX has been successfully added to your 
